Idioma:

Multi-Omics Technologies Applied to Tuberculosis Drug Discovery

Goff, Aaron ; Cantillon, Daire ; Wildner, Leticia Muraro ; Waddell, Simon J

Applied sciences, 2020-07, Vol.10 (13), p.4629 [Periódico revisado por pares]

Basel: MDPI AG

Texto completo disponível

Citações Citado por

Enviar para

Título:
Multi-Omics Technologies Applied to Tuberculosis Drug Discovery
Autor: Goff, Aaron ; Cantillon, Daire ; Wildner, Leticia Muraro ; Waddell, Simon J
Assuntos: Antimicrobial agents ; Biosynthesis ; Clinical trials ; Cytokines ; Deoxyribonucleic acid ; Discovery tools ; DNA ; Drug discovery ; Drug resistance ; Drug therapy ; Gene expression ; Genetic engineering ; Genomes ; Genomics ; Laboratories ; Lead compounds ; Metabolism ; Metabolites ; Methods ; Microbial drug resistance ; Mode of action ; Molecular biology ; Mutation ; mycobacterium ; Prevention ; Proteins ; proteomics ; RNA polymerase ; Technology application ; transcriptomics ; Tuberculosis
É parte de: Applied sciences, 2020-07, Vol.10 (13), p.4629
Descrição: Multi-omics strategies are indispensable tools in the search for new anti-tuberculosis drugs. Omics methodologies, where the ensemble of a class of biological molecules are measured and evaluated together, enable drug discovery programs to answer two fundamental questions. Firstly, in a discovery biology approach, to find new targets in druggable pathways for target-based investigation, advancing from target to lead compound. Secondly, in a discovery chemistry approach, to identify the mode of action of lead compounds derived from high-throughput screens, progressing from compound to target. The advantage of multi-omics methodologies in both of these settings is that omics approaches are unsupervised and unbiased to a priori hypotheses, making omics useful tools to confirm drug action, reveal new insights into compound activity, and discover new avenues for inquiry. This review summarizes the application of Mycobacterium tuberculosis omics technologies to the early stages of tuberculosis antimicrobial drug discovery.
Editor: Basel: MDPI AG
Idioma: Inglês

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Multi-Omics Technologies Applied to Tuberculosis Drug Discovery

Goff, Aaron ; Cantillon, Daire ; Wildner, Leticia Muraro ; Waddell, Simon J

Basel: MDPI AG

Buscando em bases de dados remotas. Favor aguardar.